Allakos (ALLK) Competitors $0.33 +0.00 (+0.93%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-0.61%) As of 04/17/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALLK vs. KOD, CHRS, FTLF, EPRX, EDIT, TIL, NMRA, PROC, FATE, and ENTAShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Kodiak Sciences (KOD), Coherus BioSciences (CHRS), FitLife Brands (FTLF), Eupraxia Pharmaceuticals (EPRX), Editas Medicine (EDIT), Instil Bio (TIL), Neumora Therapeutics (NMRA), Procaps Group (PROC), Fate Therapeutics (FATE), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Kodiak Sciences Coherus BioSciences FitLife Brands Eupraxia Pharmaceuticals Editas Medicine Instil Bio Neumora Therapeutics Procaps Group Fate Therapeutics Enanta Pharmaceuticals Allakos (NASDAQ:ALLK) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends. Which has more volatility and risk, ALLK or KOD? Allakos has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Is ALLK or KOD more profitable? Kodiak Sciences' return on equity of -84.52% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets AllakosN/A -140.87% -86.22% Kodiak Sciences N/A -84.52%-45.40% Which has stronger valuation & earnings, ALLK or KOD? Kodiak Sciences is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllakosN/AN/A-$185.70M-$1.32-0.25Kodiak SciencesN/AN/A-$260.49M-$3.36-0.85 Does the MarketBeat Community believe in ALLK or KOD? Allakos received 164 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 58.84% of users gave Allakos an outperform vote while only 27.14% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformAllakosOutperform Votes18358.84% Underperform Votes12841.16% Kodiak SciencesOutperform Votes1927.14% Underperform Votes5172.86% Do analysts prefer ALLK or KOD? Allakos presently has a consensus target price of $2.00, indicating a potential upside of 513.50%. Kodiak Sciences has a consensus target price of $9.00, indicating a potential upside of 216.46%. Given Allakos' stronger consensus rating and higher possible upside, research analysts plainly believe Allakos is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in ALLK or KOD? 84.6% of Allakos shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 16.1% of Allakos shares are held by company insiders. Comparatively, 45.3% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer ALLK or KOD? In the previous week, Kodiak Sciences had 2 more articles in the media than Allakos. MarketBeat recorded 2 mentions for Kodiak Sciences and 0 mentions for Allakos. Allakos' average media sentiment score of 0.00 beat Kodiak Sciences' score of -1.00 indicating that Allakos is being referred to more favorably in the media. Company Overall Sentiment Allakos Neutral Kodiak Sciences Negative SummaryAllakos beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks. Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.41M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.166.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.175.916.443.97Net Income-$185.70M$142.72M$3.21B$247.65M7 Day Performance1.75%4.38%2.85%1.80%1 Month Performance27.74%-12.76%-8.64%-6.98%1 Year Performance-69.25%-9.69%11.38%1.34% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.1349 of 5 stars$0.33+0.9%$2.00+513.5%-69.2%$29.41MN/A-0.16190KODKodiak Sciences3.4934 of 5 stars$2.18flat$9.00+312.8%-21.0%$114.99MN/A-0.6090Short Interest ↑Analyst RevisionNegative NewsCHRSCoherus BioSciences3.618 of 5 stars$0.97+16.6%$5.38+451.5%-47.9%$112.95M$266.96M-12.18330Analyst DowngradeNews CoverageGap DownFTLFFitLife Brands4.2338 of 5 stars$12.07+3.3%$20.50+69.8%-9.9%$111.27M$64.47M14.2820Positive NewsGap UpEPRXEupraxia Pharmaceuticals1.7821 of 5 stars$3.10+2.3%$10.50+238.7%+25.4%$111.13MN/A-4.3129EDITEditas Medicine4.0135 of 5 stars$1.32+1.5%$6.83+417.7%-77.1%$110.50M$32.31M-0.52230Analyst RevisionNews CoveragePositive NewsGap UpTILInstil Bio2.0875 of 5 stars$16.80+11.8%$114.00+578.6%+45.9%$109.64MN/A-1.45410NMRANeumora Therapeutics3.1678 of 5 stars$0.67-1.8%$9.29+1,286.3%-93.8%$108.49MN/A-0.36108PROCProcaps GroupN/A$0.95-40.3%N/A-64.6%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeFATEFate Therapeutics3.4938 of 5 stars$0.92-12.8%$5.43+487.3%-78.9%$105.93M$13.63M-0.56550News CoverageGap DownENTAEnanta Pharmaceuticals4.0354 of 5 stars$4.93+5.1%$17.25+249.9%-63.6%$105.17M$66.59M-1.00160Gap Up Related Companies and Tools Related Companies Kodiak Sciences Competitors Coherus BioSciences Competitors FitLife Brands Competitors Eupraxia Pharmaceuticals Competitors Editas Medicine Competitors Instil Bio Competitors Neumora Therapeutics Competitors Procaps Group Competitors Fate Therapeutics Competitors Enanta Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
